ArticleDiscover oncology2025
CXCL10 promotes non-small cell lung cancer (NSCLC) progression by modulating the phosphate to urate ratio (PUR).
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore the causal relationships and mechanisms between NSCLC-related genes, metabolites, and NSCLC using Mendelian Randomization (MR). The study employed differential gene expression analysis, two-sample MR analysis, and mediation analysis, utilizing NSCLC Genome-Wide Association Study (GWAS) data from the Finngen database, gene data from the eQTLGen and pQTL databases, and NSCLC expression data from the Gene Expression Omnibus (GEO) database. First, two-sample MR analysis was performed to evaluate the causal relationships between expression quantitative trait loci (eQTL) and protein quantitative trait loci (pQTL) genes and NSCLC. Violin plots were then used to validate the expression levels of these genes in NSCLC. Finally, mediation analysis was conducted to explore the mediating role of metabolites in the relationship between gene expression and NSCLC development. Our study found a significant positive association between high expression of the CXCL10 gene and increased NSCLC risk. Further mediation analysis revealed that CXCL10 promotes NSCLC development by regulating the PUR. Specifically, the mediation effect was 0.039, with a mediation proportion of 25.4% and a P-value of 0.012. This study provides new insights into the molecular mechanisms of CXCL10 in NSCLC and suggests its potential as a biomarker for future targeted therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.